Researchers at University of Glasgow have developed a new “nanokicking” technology, which directs mesenchymal stem cells to precisely differentiate into a bone material for use in fracture repairs and bone grafting. By subjecting the stem cells to ‘nanokicking’ – precise, nanoscale vibrations, while the cells are in a collagen gel, these cells can more effectively transform into bone cells capable of replenishing damaged or depleted bone mass. Current bone grafts obtained from patients themselves nearly never yield enough bone material to be clinically relevant for severe injuries, and donor bone grafts have a high risk of rejection hence, autologous stem cell grafts represent an optimal treatment option for patients suffering from any type of bone trauma or deficiency. With bone being the second most grafted tissue [behind blood], ‘nanokicking’ the patient’s own stem cells would significantly impact patient outcomes following reconstructive, maxillofacial and orthopedic surgeries.
Biostar Stem Cell Research institute has developed a protocol for the use of autologous [the patient’s own] stem cells to combat Alzheimer’s Disease with the FDA has approving Phase I and II clinicals trials for the new treatment. The process involves recovering, isolating and culturing the patient’s own stem cells. Culturing the cells results in the production of a clinically significant number of cells, enabling an extended treatment period and protocol. These cells are injected intravenously across ten treatments, using approximately 200 million cells each time. By utilizing the patient’s own stem cells to address neural degradation, the researchers anticipate the treatment may go a long way to both slow the degenerative progression of the disease, while also addressing the root cause of Alzheimer’s Disease.